May 30, 2024 06:09 PM EDTUpdated 06:57 PM
R&D
Pharma
FDA+

Gilead’s block­buster ADC Trodelvy fails blad­der can­cer con­fir­ma­to­ry study

Lei Lei Wu

News Reporter

Gilead on Thurs­day dis­closed that Trodelvy, the an­ti­body-drug con­ju­gate that is a key part of the drug­mak­er’s on­col­o­gy busi­ness, failed a Phase 3 study af­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

As­traZeneca’s Truqap edges clos­er to prostate can­cer la­bel ex­pan­sion with Phase 3 win

A service from the Financial Times